Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.33 |
| ▸ | TDO2 | P48775 | 3/20 | 0.32 |
| ▸ | NOS1 | P29475 | 3/20 | 0.31 |
| ▸ | IDO1 | P14902 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10872204 | 0.77 | CYP2C19 (0.38) | CYP11B2CYP11B1NOS1 | |
| SCHEMBL4833974 | 0.74 | CYP11B1 (0.44) | CYP11B2CYP11B1NOS1 | |
| SCHEMBL2359179 | 0.73 | NOS1 (0.52) | CYP11B2CYP11B1TDO2NOS1NOTUM | |
| SCHEMBL27905454 | 0.70 | GABRA5 (0.33) | TDO2IDO1HTR1AHTR7HTR6 | |
| SCHEMBL899141 | 0.69 | ERN1 (0.34) | CYP11B2CYP11B1TDO2IDO1 | |
| SCHEMBL6928773 | 0.69 | CYP11B1 (0.48) | CYP11B2CYP11B1POLB | |
| Hydrochloric Acid SCHEMBL7657123 | 0.68 | CYP11B1 (0.47) | CYP11B2CYP11B1POLB | |
| SCHEMBL9473672 | 0.68 | NOTUM (0.43) | CYP11B2CYP11B1TDO2NOS1IDO1 | |
| SCHEMBL898835 | 0.67 | GABRA1 (0.50) | CYP11B2CYP11B1 | |
| SCHEMBL24013546 | 0.67 | CYP11B1 (0.36) | CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621907-A1 | FUNGICIDAL IMIDAZOLES | E.I. Du Pont De Nemours And Company (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | EI DU PONT DE NEMOURS AND COMPANY (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012044650-A1 | FUNGICIDAL IMIDAZOLES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143929-A1 | FUNGICIDAL IMIDAZOLES | CYP1A1, CYP1B1, CYP2E1 | CYP11B2 114/4885CYP11B1 86/4885TBXAS1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.